10.63 USD
↗ 0.20 (1.92%)AT CLOSE (03:59 PM EDT)
MiNK Therapeutics, Inc. Common Stock
INKTNASDAQ • USD
10.60
↘ 0.03 (0.28%)
POST MARKET (AS OF 05:07 PM EDT)
Post Market
AS OF 05:07 PM EDT
10.60
↘ 0.03 (0.28%)
Market: OPEN
MiNK Therapeutics, Inc. Common Stock (INKT) trades at $10.60 per share. Technical and fundamental signals converge bearish — technicals rate "Sell" while fundamentals read "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, exceptional Return on Equity (81.0%) and a bearish Death Cross on the long-term moving averages.
Technical & fundamental data as of Oct 27, 2026.
Open?$10.48
High?$10.85
Low?$10.41
Prev. Close?$10.43
Volume?10.1K
Avg. Volume?17.4K
VWAP?$10.60
Rel. Volume?0.58x
Bid / Ask
Bid?$8.60 × 100
Ask?$13.06 × 100
Spread?$4.46
Midpoint?$10.83
Valuation & Ratios
Market Cap?53.2M
Shares Out?5.1M
Float?2.0M
Float %?39.2%
P/E Ratio?N/A
P/B Ratio?-3.79
EPS?-$2.23
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
Themes
Employees
15
Market Cap
53.2M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2021-10-15
Address
149 FIFTH AVENUE
NEW YORK, NY 10010
Phone: 212-994-8250
NEW YORK, NY 10010
Phone: 212-994-8250
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?50
Short Sent.?64
Piotroski F-Score?0/9Weak
Altman Z-Score?-26.22Distress
Confidence?49%Low
Short InterestLow
Short % of Float?2.39%Low
Short Interest?47.8K
Days to Cover?2.4
Free Float2.0M
Avg Daily Volume20.0K
Settlement Date2026-10-15
Financial Health
Current Ratio?1.23Adequate
Quick Ratio?1.23Adequate
Cash Ratio?1.16Strong
Debt/Equity?-0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?-3.79CHEAP▾
S&P97
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-3.8CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?81.0%STRONG▾
Peers50
S&P97
ROA?-118.2%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-6830483
Enterprise Value?$44.4M
Fundamentals ratios updated end of day